(9ci)-1-[[(9h-芴-9-基甲氧基)羰基]氨基]-环戊烷乙酸 | 282524-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: (9ci)-1-[[(9h-芴-9-基甲氧基)羰基]氨基]-环戊烷乙酸
• 中文别名: FMOC-1-氨基-环戊烷乙酸
• 英文名称: Fmoc-2-(1-aminocyclopentyl)acetic acid
• 英文别名: (1-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}cyclopentyl)acetic acid；2-[1-(9H-fluoren-9-ylmethoxycarbonylamino)cyclopentyl]acetic acid
• CAS: 282524-99-6
• 化学式: C₂₂H₂₃NO₄
• 分子量: 365.429
• InChiKey: ZPLSFORKBASRNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-羟基-1,3-二氢苯并[c][1,2]氧杂硼杂环烷-6-羧酸 、 (9ci)-1-[[(9h-芴-9-基甲氧基)羰基]氨基]-环戊烷乙酸 、 (2S,4S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-(9H-fluoren-9-ylmethoxycarbonylamino)pyrrolidine-2-carboxylic acid 在 2-chlorotrityl chloride polystyrene resin 、 N,N-二异丙基乙胺 、 哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(1-((2S,4S)-1-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamido)pyrrolidine-2-carboxamido)cyclopentyl)acetic acid
  参考文献：
  名称：

  WO2023/225534

  摘要：

  公开号：

文献信息

• Seco macrolide compounds
  申请人：FIDELTA D.O.O.

  公开号：US10919910B2

  公开（公告）日：2021-02-16

  The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

  本发明涉及仲环（开环）大环内酯化合物、其制备工艺、将所述仲环大环内酯化合物用作制备大环内酯基大环内酯的中间体、从所述仲环大环内酯化合物中获得大环内酯基大环内酯、制备大环内酯基大环内酯的工艺、包含大环内酯基大环内酯的药物组合物，以及将大环内酯基大环内酯用作治疗剂。
• SECO MACROLIDE COMPOUNDS
  申请人：FIDELTA D.O.O.

  公开号：US20210198278A1

  公开（公告）日：2021-07-01

  The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.
• [EN] COMPOUNDS FOR MODULATING IL-17
  申请人：ENSEMBLE THERAPEUTICS CORPORATION

  公开号：WO2014066726A2

  公开（公告）日：2014-05-01

  [EN] The invention relates generally to compounds and their therapeutic use. More particularly, the invention relates to compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17 associated disorders.
• WO2023/225534
  申请人：——

  公开号：——

  公开（公告）日：——